Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Biotechnology

Healthcare
$0.46 -0.01%

-$0.00 today

Market cap
$57.32M
Beta
0.96
P/E (TTM)
-2.5
EPS (TTM)
-$0.52
52W Low $1.00High $3.06

Volume 2.23M

Average 1.99M

MIST Interest Income

Income earned on cash, deposits, and investments held by the company.

Milestone Pharmaceuticals Inc.NASDAQ: MIST

Interest Income · Q1 FY2026 · quarter ended Mar 2026

Interest income growth accelerates

Q1 FY2026 interest income of $1.73M rose 148.5% year over year, ahead of the +2.3% change in trailing-twelve-month interest income. Sequentially, it rose 107.9% from the prior quarter. Over 3 fiscal years it compounded at +32.5% a year.

Context

  • Interest income amounted to 188.9% of revenue in FY2025.
  • Interest income increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +148.5% holds above the trailing-twelve-month pace of +2.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.73M+107.9% QoQ
Last fiscal yearDec 2025
$2.92M-29.9% YoY
LTMMar 2026
$3.96M+2.3% YoY
Interest Income past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+148.5%——
1 year-29.9%——
3-year CAGR+32.5%——
5-year CAGR——
10-year CAGR——

Interest Income history

USD · from the income statement

Latest · FY2025
2.92M USD
Year-over-year change
-29.9%
4-year CAGR
+90.9%

Interest Income vs competitors

How MIST compares with its peers on the latest reported figures

  • Peers report in different currencies, so interest income is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +2.3% is the highest of 8, against a peer median of -28.6%.
  • Interest income amounts to 221.7% of revenue for MIST, versus a peer median of 47.3%.
MIST Competitors
Interest Income for MIST and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CRBPCorbus Pharmaceuticals Holdings, Inc.LTM Mar 2026$5.25M USD-28.4%——
PEPGPepGen Inc.LTM Mar 2026$4.15M USD-36.5%+12.9%—
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026$3.96M USD+2.3%+32.5%221.7%
CRDFCardiff Oncology, Inc.LTM Mar 2026$2.67M USD-18.5%+25.2%508.4%
MOLNMolecular Partners AGLTM Mar 2026CHF 1.48M CHF-47.8%+8.4%—
IPHAInnate Pharma S.A.FY2025€1.32M EUR-45.9%+34.1%47.3%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$1.02M USD-28.6%-12.8%32.2%
ELTXElicio Therapeutics, Inc.LTM Mar 2026$723K USD-13.6%+128.8%—
Peer median (excluding MIST) —-28.6%+19.0%47.3%

Competitors are the stored peer set for MIST. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue15M5M1M01.55M
Cost of Revenue0000114K
Gross Profit15M5M1M01.43M
Gross Margin100.0%100.0%100.0%—92.6%
Research & Development38.67M39.83M31.05M14.36M18.11M
Selling, General & Admin19.4M24.81M31.05M27.75M17.27M
Operating Expenses58.07M64.64M62.1M42.1M63.92M
Depreciation & Amortization93K89K92K105K114K
EBITDA(42.76M)(58.3M)(57.04M)(37.83M)(59.45M)
EBITDA Margin-285.1%-1166.0%-5703.9%—-3845.5%
Operating Income(43.07M)(59.64M)(61.1M)(42.1M)(62.49M)
Operating Margin-287.2%-1192.8%-6109.8%—-4041.7%
Interest Income220K1.25M3.97M4.16M2.92M
Interest Expense002.55M(3.58M)3.84M
Other Income / Expenses220K1.25M1.41M583K(918K)
Income Before Tax(42.85M)(58.39M)(59.69M)(41.52M)(63.4M)
Pre-Tax Margin-285.7%-1167.8%-5968.5%—-4101.1%
Income Tax Expense0000(345K)
Net Income(42.85M)(58.39M)(59.69M)(41.52M)(63.06M)
Net Margin-285.7%-1167.8%-5968.5%—-4078.8%
EPS (Basic)(1.02)(1.35)(1.39)(0.67)(0.75)
EPS (Diluted)(1.02)(1.35)(1.39)(0.67)(0.75)
Weighted Avg Shares41.83M42.45M42.96M62.21M83.88M
Weighted Avg Shares (Diluted)41.83M42.45M42.96M62.21M83.88M

Milestone Pharmaceuticals Inc.

NASDAQ:MIST

Intrinsic Alpha fair value

Locked

Current Price

$0.46

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.